167 related articles for article (PubMed ID: 36583633)
1. Eptinezumab improved patient-reported outcomes and quality of life in patients with migraine and prior preventive treatment failures.
Goadsby PJ; Barbanti P; Lambru G; Ettrup A; Christoffersen CL; Josiassen MK; Phul R; Sperling B
Eur J Neurol; 2023 Apr; 30(4):1089-1098. PubMed ID: 36583633
[TBL] [Abstract][Full Text] [Related]
2. Effects of eptinezumab on self-reported work productivity in adults with migraine and prior preventive treatment failure in the randomized, double-blind, placebo-controlled DELIVER study.
Barbanti P; Goadsby PJ; Lambru G; Ettrup A; Christoffersen CL; Josiassen MK; Phul R; Sperling B
J Headache Pain; 2022 Dec; 23(1):153. PubMed ID: 36460983
[TBL] [Abstract][Full Text] [Related]
3. Long-term effectiveness of eptinezumab in patients with migraine and prior preventive treatment failures: extension of a randomized controlled trial.
Ashina M; Tepper SJ; Gendolla A; Sperling B; Ettrup A; Josiassen MK; Starling AJ
J Headache Pain; 2023 Nov; 24(1):155. PubMed ID: 37985968
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures (DELIVER): a multi-arm, randomised, double-blind, placebo-controlled, phase 3b trial.
Ashina M; Lanteri-Minet M; Pozo-Rosich P; Ettrup A; Christoffersen CL; Josiassen MK; Phul R; Sperling B
Lancet Neurol; 2022 Jul; 21(7):597-607. PubMed ID: 35716692
[TBL] [Abstract][Full Text] [Related]
5. Eptinezumab treatment initiated during a migraine attack is associated with meaningful improvement in patient-reported outcome measures: secondary results from the randomized controlled RELIEF study.
McAllister P; Winner PK; Ailani J; Buse DC; Lipton RB; Chakhava G; Josiassen MK; Lindsten A; Mehta L; Ettrup A; Cady R
J Headache Pain; 2022 Feb; 23(1):22. PubMed ID: 35130832
[TBL] [Abstract][Full Text] [Related]
6. Effects of Intravenous Eptinezumab vs Placebo on Headache Pain and Most Bothersome Symptom When Initiated During a Migraine Attack: A Randomized Clinical Trial.
Winner PK; McAllister P; Chakhava G; Ailani J; Ettrup A; Krog Josiassen M; Lindsten A; Mehta L; Cady R
JAMA; 2021 Jun; 325(23):2348-2356. PubMed ID: 34128999
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of eptinezumab for migraine prevention in patients with prior preventive treatment failures: subgroup analysis of the randomized, placebo-controlled DELIVER study.
Ashina M; Lanteri-Minet M; Ettrup A; Christoffersen CL; Josiassen MK; Phul R; Sperling B; Pozo-Rosich P
Cephalalgia; 2023 May; 43(5):3331024231170807. PubMed ID: 37125484
[TBL] [Abstract][Full Text] [Related]
8. Eptinezumab improved patient-reported outcomes in patients with migraine and medication-overuse headache: Subgroup analysis of the randomized PROMISE-2 trial.
Starling AJ; Cowan RP; Buse DC; Diener HC; Marmura MJ; Hirman J; Brevig T; Cady R
Headache; 2023 Feb; 63(2):264-274. PubMed ID: 36633219
[TBL] [Abstract][Full Text] [Related]
9. Patient-identified most bothersome symptom in preventive migraine treatment with eptinezumab: A novel patient-centered outcome.
Lipton RB; Dodick DW; Ailani J; McGill L; Hirman J; Cady R
Headache; 2021 May; 61(5):766-776. PubMed ID: 34013992
[TBL] [Abstract][Full Text] [Related]
10. Eptinezumab for the prevention of chronic migraine: efficacy and safety through 24 weeks of treatment in the phase 3 PROMISE-2 (Prevention of migraine via intravenous ALD403 safety and efficacy-2) study.
Silberstein S; Diamond M; Hindiyeh NA; Biondi DM; Cady R; Hirman J; Allan B; Pederson S; Schaeffler B; Smith J
J Headache Pain; 2020 Oct; 21(1):120. PubMed ID: 33023473
[TBL] [Abstract][Full Text] [Related]
11. Rapid resolution of migraine symptoms after initiating the preventive treatment eptinezumab during a migraine attack: results from the randomized RELIEF trial.
Ailani J; McAllister P; Winner PK; Chakhava G; Krog Josiassen M; Lindsten A; Sperling B; Ettrup A; Cady R
BMC Neurol; 2022 Jun; 22(1):205. PubMed ID: 35659622
[TBL] [Abstract][Full Text] [Related]
12. Patient-reported outcomes, health-related quality of life, and acute medication use in patients with a ≥ 75% response to eptinezumab: subgroup pooled analysis of the PROMISE trials.
Lipton RB; Charleston L; Tassorelli C; Brevig T; Hirman J; Cady R
J Headache Pain; 2022 Feb; 23(1):23. PubMed ID: 35130836
[TBL] [Abstract][Full Text] [Related]
13. Efficacy, tolerability, and safety of eptinezumab in patients with a dual diagnosis of chronic migraine and medication-overuse headache: Subgroup analysis of PROMISE-2.
Diener HC; Marmura MJ; Tepper SJ; Cowan R; Starling AJ; Diamond ML; Hirman J; Mehta L; Brevig T; Sperling B; Cady R
Headache; 2021 Jan; 61(1):125-136. PubMed ID: 33314079
[TBL] [Abstract][Full Text] [Related]
14. Optimization of acute medication use following eptinezumab initiation during a migraine attack: post hoc analysis of the RELIEF study.
Cady R; Lipton RB; Buse DC; Josiassen MK; Lindsten A; Ettrup A
J Headache Pain; 2022 Jul; 23(1):91. PubMed ID: 35902796
[TBL] [Abstract][Full Text] [Related]
15. Evaluating the clinical utility of the patient-identified most bothersome symptom measure from PROMISE-2 for research in migraine prevention.
Lipton RB; Goadsby PJ; Dodick DW; McGinley JS; Houts CR; Wirth RJ; Kymes S; Ettrup A; Østerberg O; Cady R; Ashina M; Buse DC
Headache; 2022 Jun; 62(6):690-699. PubMed ID: 35466430
[TBL] [Abstract][Full Text] [Related]
16. Responder rates with eptinezumab over 24 weeks in patients with prior preventive migraine treatment failures: post hoc analysis of the DELIVER randomized clinical trial.
Ashina M; Lipton RB; Ailani J; Versijpt J; Sacco S; Mitsikostas DD; Christoffersen CL; Sperling B; Ettrup A
Eur J Neurol; 2024 Feb; 31(2):e16131. PubMed ID: 37955557
[TBL] [Abstract][Full Text] [Related]
17. Shift in diagnostic classification of migraine after initiation of preventive treatment with eptinezumab: post hoc analysis of the PROMISE studies.
Pozo-Rosich P; Dodick DW; Ettrup A; Hirman J; Cady R
BMC Neurol; 2022 Oct; 22(1):394. PubMed ID: 36284281
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of eptinezumab in patients with chronic migraine and medication-overuse headache: a randomized, double-blind, placebo-controlled study.
Yu S; Zhou J; Luo G; Xiao Z; Ettrup A; Jansson G; Florea I; Ranc K; Pozo-Rosich P
BMC Neurol; 2023 Dec; 23(1):441. PubMed ID: 38102535
[TBL] [Abstract][Full Text] [Related]
19. Eptinezumab Demonstrated Efficacy Regardless of Prior Preventive Migraine Treatment Failure Type: Post Hoc Analyses of the DELIVER Study.
Pozo-Rosich P; Ashina M; Tepper SJ; Jensen S; Boserup LP; Josiassen MK; Sperling B
Neurol Ther; 2024 Apr; 13(2):339-353. PubMed ID: 38236314
[TBL] [Abstract][Full Text] [Related]
20. Quantity changes in acute headache medication use among patients with chronic migraine treated with eptinezumab: subanalysis of the PROMISE-2 study.
Cowan RP; Marmura MJ; Diener HC; Starling AJ; Schim J; Hirman J; Brevig T; Cady R
J Headache Pain; 2022 Sep; 23(1):115. PubMed ID: 36068494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
